erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
�now we know the astonishing truth that some patients are waiting a year or more just to get treatment. it�s simply not good enough.�
.
.
the statistics i�m quoting reveal a problem on the level of a tsunami sweeping across the whole of america and europe.
.
.
mayo clinic: "migraine: diagnosis & treatment," "monoclonal antibody drugs for cancer: how they work."
. in washington before heading to baltimore for saturday's broadcast of
.
activity
.
.
.
.